SS-31 Peptide For Sale
Buy SS-31 peptide: 10mg, 25mg, 30mg, 50mg or 60mg listed purchase quantities. Compare live prices across 8 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy SS-31 peptide starting at $38.25/purchase from 8 listed vendors. Compare 10mg, 25mg, 30mg, 50mg and 60mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does SS-31 cost per month?
An illustrative SS-31 cost model works out to about $358.11 per month: Peptira's listed 50 mg purchase quantity at $118.15 with code WPA, divided into 5 mg amounts daily. This quantity provides 10.0 nominal portions — about 1.4 weeks at the selected cadence, before preparation losses or stability limits — for roughly $82.71 per week or $358.11 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 10,039 calculator runs; overall cadence comes from 3,579 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About SS-31
In clinical trialsAlso known as: Elamipretide · MTP-131 · BendaviaSS-31 (elamipretide) is a mitochondria-targeted research peptide most often sourced for mitochondrial-health and recovery protocols. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
What to check before you buy SS-31:
- A third-party COA showing ≥98–99% purity by HPLC plus mass-spec confirmation of the peptide sequence and mass — not just an in-house "tested" stamp.
- A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
- Accurate vial fill: a 50mg label should assay close to 50mg. Under-filled or mislabeled vials are a common failure mode, and they throw off every reconstitution calculation.
Elamipretide has been evaluated in primary mitochondrial myopathy (MMPOWER-3, Phase 3), heart failure with preserved ejection fraction (PROGRESS-HF), Barth syndrome (TAZPOWER, Phase 2/3), and Leber hereditary optic neuropathy.[2][3] MMPOWER-3 missed its primary endpoint in 2019; subsequent Barth syndrome work supported a pending FDA submission.
Regulatory: Not FDA-approved as of 2024 (NDA for Barth syndrome under FDA review). Research-grade SS-31 is for non-clinical use only.
SS-31: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how SS-31 works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
SS-31 — clinical name elamipretide, also known as MTP-131 and Bendavia — is a synthetic water-soluble tetrapeptide (D-Arg-2′,6′-dimethyl-Tyr-Lys-Phe-NH2) developed by Stealth BioTherapeutics that selectively accumulates in the inner mitochondrial membrane at concentrations several thousand-fold higher than in cytosol.[1][6] Once inside, it binds cardiolipin — a phospholipid unique to the inner mitochondrial membrane that organises the electron-transport-chain supercomplexes (Complex I-III-IV) and stabilises ATP synthase. By binding cardiolipin without depleting it, SS-31 preserves cristae architecture, tightens electron-transport-chain coupling, reduces electron leakage to oxygen, and lowers mitochondrial reactive-oxygen-species generation.[1][6] The downstream effect is improved ATP-synthesis efficiency specifically in dysfunctional mitochondria — ischaemic, aged, or mutation-affected — without changing function in healthy mitochondria. This selectivity for diseased mitochondria is the conceptual basis for pursuing elamipretide in primary mitochondrial disorders rather than as a general antioxidant. The molecule is administered subcutaneously in clinical trials at 40 mg once daily.
Active research areas
- Primary mitochondrial myopathy (MMPOWER-3, Phase 3)The MMPOWER-3 Phase 3 trial of subcutaneous elamipretide vs. placebo in adults with primary mitochondrial myopathy missed its primary endpoint (6-minute walk test distance) in 2019, despite a positive Phase 2 dose-escalation signal.[2][4] The failure complicated the case for the molecule in PMM but left the broader cardiolipin-binding mechanism intact for other indications.
- Barth syndrome (TAZPOWER, Phase 2/3)Reid Thompson et al. ran TAZPOWER as a Phase 2/3 randomised crossover trial followed by an open-label extension in adolescents and adults with Barth syndrome — a rare X-linked cardiolipin-remodelling disorder.[5] The double-blind crossover phase did not meet its primary endpoints, but the open-label extension showed improvements in functional and biomarker measures that supported a Stealth BioTherapeutics NDA submission. The FDA Cardiovascular and Renal Drugs Advisory Committee reviewed the package in October 2024.[8]
- Heart failure (PROGRESS-HF)PROGRESS-HF tested elamipretide in heart failure with reduced ejection fraction.[7] The mechanistic rationale — failing cardiomyocyte mitochondria with destabilised cardiolipin and uncoupled electron transport — is plausible for HFrEF, but the program has produced mixed clinical readouts.
- Leber hereditary optic neuropathy and other rare mitochondrial disordersSmaller exploratory trials have evaluated elamipretide in Leber hereditary optic neuropathy and in age-related macular degeneration, building on the cardiolipin-binding mechanism and the high mitochondrial density of retinal photoreceptors.[6] These are early-stage signals, not confirmatory programs.
- Regulatory statusElamipretide is not FDA-approved as of May 2026; the Barth syndrome NDA reviewed by the FDA Advisory Committee in October 2024 produced a mixed vote and the program remains under review.[8] Research-grade "SS-31" sold as a peptide is for non-clinical use only.
Open questions & leading hypotheses (2)
- Hypothesis: Cardiolipin binding by SS-31 produces sufficient functional benefit in primary mitochondrial myopathy to translate into clinical improvement, despite the negative MMPOWER-3 readout.Evidence: The mechanism is well-characterised, and the Phase 2 dose-escalation study showed dose-dependent improvements in 6-minute walk distance.[1][2][6] Counter-evidence: MMPOWER-3 was the confirmatory Phase 3 trial and it missed its primary endpoint;[4] mechanism plausibility is necessary but not sufficient, and the gap between Phase 2 and Phase 3 in this program illustrates the limits of inferring clinical benefit from a strong mechanistic story.
- Hypothesis: SS-31 has a broader anti-ageing or "mitochondrial-health" effect in healthy adults at the doses used in research-peptide protocols.Evidence: The molecule selectively accumulates in mitochondria and preserves cristae architecture and ATP-synthesis efficiency in dysfunctional mitochondria.[1][6] Counter-evidence: the published evidence is in disease populations (PMM, Barth, HF) where mitochondria are clearly dysfunctional; SS-31 has not been shown to change function in healthy mitochondria, which is by design. The "longevity" framing extrapolates well beyond the published clinical evidence base.
What community users report
Anecdotal — not controlled-trial evidence
Across r/Peptides and r/longevity, SS-31 is most often framed as a research "mitochondrial-health" intervention, with subcutaneous dosing at 5–10 mg per day in 4–8-week cycles being the most commonly reported pattern.[9][10] Reported subjective effects include improved exercise tolerance, reduced perceived fatigue, and faster recovery from prolonged endurance work; users routinely note that the published clinical data is in disease populations and that there is essentially no controlled evidence for healthy-adult use. Many threads explicitly track the Stealth BioTherapeutics Barth syndrome NDA status as a proxy for how seriously the molecule should be taken. **These reports are anecdotal and have not been validated in controlled trials.** They describe what people who have already chosen to use SS-31 are experiencing, not whether any specific dose, schedule, or duration is safe or effective in healthy adults.
Sources & references (10)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013;24:1250–1261. · PMID: 23813215 link
- [2]Karaa A et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 2018;90:e1212–e1221. · PMID: 29500292 link
- [3]ClinicalTrials.gov: TAZPOWER (NCT03098797) — elamipretide in Barth syndrome link
- [4]Karaa A et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy (MMPOWER-3). J Cachexia Sarcopenia Muscle 2020;11:909–918. · PMID: 32253831 link
- [5]Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (TAZPOWER). Genet Med 2021;23:471–478. · PMID: 33077872 link
- [6]Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol 2014;171:2029–2050. · PMID: 24117165 link
- [7]ClinicalTrials.gov: PROGRESS-HF (NCT02814097) — elamipretide in heart failure with reduced ejection fraction. link
- [8]FDA Briefing Document — Cardiovascular and Renal Drugs Advisory Committee meeting on Stealth BioTherapeutics' elamipretide NDA for Barth syndrome, Oct 2024. link
- [9]Community report — r/Peptides SS-31 / elamipretide protocol threads (subreddit), accessed May 2026. link
- [10]Community report — r/longevity SS-31 mitochondrial discussions (subreddit), accessed May 2026. link
What SS-31 Costs Right Now
WPA currently tracks SS-31 from 8 distinct vendors across 11 separate SS-31 listings. In-stock SS-31 vials run from $38.25 to $161.99 — a 4.2x spread for the same compound. Southern Aminos holds the lowest sticker price at $38.25. Normalized to milligrams, SS-31 costs $2.36/mg to $5.67/mg on this page. The best per-milligram value is the listed 50 mg purchase quantity from Peptira.
SS-31 is stocked in 5 sizes: 10 mg listed quantity; vial count not recorded; 25 mg listed quantity; vial count not recorded; 30 mg listed quantity; vial count not recorded; 50 mg listed quantity; vial count not recorded; 60 mg listed quantity; vial count not recorded. 10 of the 11 tracked listings are in stock right now. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the SS-31 listings WPA tracks are: Peptira — 50mg at $118.15 ($2.36/mg), COA purity 99.95%; Felix Chem — 60mg at $161.99 ($2.70/mg), COA purity 99.94%; LA Peptides — 50mg at $135 ($2.70/mg), COA purity 99.90%; Glow Aminos — 50mg at $139.40 ($2.79/mg), COA purity 99.69%; EZ Peptides — 30mg at $88.20 ($2.94/mg).
SS-31 COA Coverage Across Tracked Vendors
10 of the 11 tracked SS-31 listings (91%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 10 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.60% to 99.95%. 9 listings record more SS-31 in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 8/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the SS-31 offer. WPA's listing fields do not establish that a report was independently verified.
SS-31 Calculator Input Observations
In lifetime SS-31 calculator inputs, 5mg is the most frequent entered amount (2,598 of 10,041 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (767 of 3,579 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 5mg, Weekly (1x/wk) is most frequent (254 of 1,146 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 60 mg of listed product divided by 5 mg gives roughly 12 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
SS-31 Discount Codes
11 of the 11 tracked SS-31 listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About SS-31
SS-31 (elamipretide) is a mitochondria-targeted research peptide most often sourced for mitochondrial-health and recovery protocols. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
SS-31 is tracked under the Performance Peptides category on WPA. Its reported half-life is ~2–3 hours. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved as of 2024 (NDA for Barth syndrome under FDA review).
How to Read the SS-31 Comparison
- Price per milligram — Every SS-31 listing is normalized to $2.36/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 10 SS-31 listings are marked for COA availability, and 10 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The SS-31 comparison includes 10mg, 25mg, 30mg, 50mg, and 60mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each SS-31 listing, refreshed on a recurring basis.
Frequently Asked Questions: SS-31
Is it legal and safe to buy SS-31 for research?
In the US, SS-31 is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. SS-31 (elamipretide) is an investigational mitochondrial-targeted peptide with no approved human form, sold for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 11 SS-31 listings from 8 vendors, 10 of them in stock.
How do I verify a SS-31 COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific SS-31 batch. Check that the report identifies the compound (actually SS-31 / elamipretide, not a lookalike or an underdosed vial), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For SS-31 specifically, 10 of 11 tracked listings (91%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 10 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 8/26.
Which SS-31 vendor should I pick?
There's no single "best" SS-31 vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. 8 vendors currently carry SS-31, and Peptira holds the best true value at $2.36/mg on the 50 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does SS-31 cost — and how do I know I'm not overpaying?
Judge SS-31 by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It most often ships in larger 30 mg vials, and those bigger vials lower $/mg sharply. Tracked SS-31 listings currently run $2.36/mg to $5.67/mg across 10mg, 25mg, 30mg, 50mg, 60mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much SS-31 do I need for one full cycle?
In lifetime SS-31 calculator inputs, 5mg is the most frequent entered amount (2,598 of 10,041 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (767 of 3,579 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 5mg, Weekly (1x/wk) is most frequent (254 of 1,146 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 60 mg purchase quantity by 5 mg gives roughly 12 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for SS-31?
Participating SS-31 vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 11 of the 11 tracked SS-31 listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Where can I compare SS-31 prices and listing details?
This comparison shows 11 tracked listings for SS-31 in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.